AKT1 and hepatocellular carcinoma: The most direct approach to inhibit PI3K/AKT pathway is to directly target PI3K itself and such inhibitors, including LY294002 and wortmannin targeting the catalytic site of p110, have been extensively used as effective research tools for investigation of PI3K/AKT in HCC [34,35].